Figure 2.

Cumulative renal and patient survival after kidney biopsy in early IgAN patients. The primary endpoint is free of death or end stage renal disease. The number of patients remaining at 60, 120, 180, 240, 300 and 360 months of follow–up are shown at the bottom.